Etiology

The etiology of ovarian cancer is poorly understood.

Inherited genetic mutations in BRCA1 or BRCA2 represent a significant risk factor for ovarian cancer.[10][11][12][13]​ Ovarian cancer associated with BRCA mutations is usually high-grade and predominantly serous or endometrioid.[13]

An increased risk of ovarian cancer (and other gynecologic cancers) is also found in patients with Lynch syndrome (formerly referred to as hereditary nonpolyposis colorectal cancer), a rare hereditary condition involving mutations of DNA mismatch repair genes (including MSH2, MLH1, MSH6, and PMS2) and deletions in the EPCAM gene.[14][15]

Other gene mutations associated with hereditary ovarian cancer (as well as breast and other cancers) include ATM, BRIP1, NBN, PALB2, STK11, RAD51C, and RAD51D.[16][17][18]​​​​​

Studies of prophylactic salpingo-oophorectomy in women with BRCA mutations have revealed that many early cancers in these women arise in the fallopian tube, and that the distal fimbrial portion is the most common site of origin.[4][19][20][21][22][23] Additionally, serous tubal intraepithelial carcinoma (STIC) has been identified as a precursor lesion for high-grade serous ovarian carcinoma, the most common type of epithelial ovarian cancer.[4][19][22][23]

Pathophysiology

Epithelial ovarian cancer does not typically invade into organ space parenchyma, but instead attaches to the surface of organs. Tumor cells implant along the lining of the peritoneal cavity (local advancement), bowel mesentery, and liver capsule, indicating metastatic disease. Malignant transformation may be related to tumor suppressor gene mutations (e.g., BRCA and TP53) for high-grade tumors, and mutations of proto-oncogenes (e.g., BRAF and KRas) for low-grade tumors.[24][25][26][27]

Exfoliated cancer cells follow the natural circulation of the peritoneal fluid, along the right paracolic gutter and subdiaphragmatic space. Thus, the right liver edge and diaphragm peritoneum are common sites of tumor implantation. The omentum also is a common site of tumor implantation.[Figure caption and citation for the preceding image starts]: Omentum infiltrated with tumorFrom the collection of Justin C. Chura, MD, Cancer Treatment Centers of America, Philadelphia, PA [Citation ends].com.bmj.content.model.Caption@6c5182df The initial spread pattern of ovarian cancer is by direct spread or lymphatic drainage. Hematogenous dissemination typically occurs late in the disease process.[28]

Classification

World Health Organization (WHO) classification of female genital tumors (2020)[5]​​

Epithelial ovarian tumors are classified by cell type (e.g., serous, endometrioid, mucinous, clear cell, Brenner, or seromucinous) and atypia (e.g., malignant, borderline, or benign).

Serous tumors

  • Malignant

    • Low-grade serous carcinoma

    • High-grade serous carcinoma

  • Carcinoma in situ and grade III intraepithelial neoplasia

    • Serous carcinoma, noninvasive, low-grade

    • Serous borderline tumor, micropapillary variant

  • Borderline

    • Serous borderline tumor

  • Benign

    • Serous cystadenoma

    • Serous surface papilloma

    • Serous adenofibroma

    • Serous cystadenofibroma

Endometrioid tumors

  • Malignant

    • Endometrioid adenocarcinoma

    • Seromucinous carcinoma

  • Borderline

    • Endometrioid borderline tumor

  • Benign

    • Endometrioid cystadenoma

    • Endometrioid adenofibroma

Mucinous tumors

  • Malignant

    • Mucinous adenocarcinoma

  • Borderline

    • Mucinous borderline tumor

  • Benign

    • Mucinous cystadenoma

    • Mucinous adenofibroma

Clear cell tumors

  • Malignant

    • Clear cell adenocarcinoma

  • Borderline

    • Clear cell borderline tumor

  • Benign

    • Clear cell cystadenoma

    • Clear cell adenofibroma

Brenner tumors

  • Malignant

    • Malignant Brenner tumor

  • Borderline

    • Borderline Brenner tumor

  • Benign

    • Brenner tumor

Seromucinous tumors

  • Borderline

    • Seromucinous borderline tumor

  • Benign

    • Seromucinous cystadenoma

    • Seromucinous adenofibroma

Use of this content is subject to our disclaimer